financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Eli Lilly And Company
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Eli Lilly And Company
Jun 11, 2024
03:25 PM EDT, 06/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target to $990 from $940, reflecting a 51.7x multiple on our 2025 EPS estimate, above LLY's historical forward P/E average. We maintain our 2024 EPS estimate at...
Understanding Section 7702 plans
Understanding Section 7702 plans
Jun 11, 2024
Key takeaways Section 7702 of the IRS tax code outlines the criteria that life insurance policies must meet to qualify for tax advantages. The term '7702 plan' is a loose marketing term, not a specific type of life insurance policy. It typically refers to the tax treatment of cash value life insurance policies, which can include whole, universal, variable...
Research Alert: CFRA Keeps Hold Opinion On Shares Of Inspire Medical Systems, Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Inspire Medical Systems, Inc.
Jun 11, 2024
11:15 AM EDT, 06/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our 12-month price target to $175 from $225 due to recent market movements, based on a forward P/E of 233x our 2025 EPS estimate of $0.75, a discount...
Research Alert: CFRA Initiates Coverage On Celsius Holdings, Inc. With Hold Opinion
Research Alert: CFRA Initiates Coverage On Celsius Holdings, Inc. With Hold Opinion
Jun 11, 2024
01:05 PM EDT, 06/11/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We set our 12-month target at $65, representing an estimated 2025 P/E of 43.3x. We initiate coverage at Hold, as we see adj-EPS growth to $1.10 in 2024 and $1.50...
Copyright 2023-2026 - www.financetom.com All Rights Reserved